Hyloris Pharmaceuticals
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Boulevard Gustave Kleyer 17, Liege, Wall...Phone Number
+32 43460207Website
www.hyloris.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Hyloris Pharmaceuticals
Hyloris is a specialty pharmaceutical company dedicated to innovating and optimizing existing medications to meet unmet healthcare needs. The company focuses on reformulation, repurposing, and developing new chemical entities, leveraging established regulatory pathways to streamline market entry. With a diverse portfolio of 28 products, including value-added medicines and high-barrier generics, Hyloris aims to improve therapy outcomes for patients and healthcare professionals. Their strategic approach emphasizes faster innovation at reduced costs and risks, targeting continuous growth and shareholder value.Explore more
Hyloris Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hyloris Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Hyloris Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Hyloris Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Hyloris Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Hyloris Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Hyloris Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hyloris Pharmaceuticals
Click to see if Hyloris Pharmaceuticals had a recent Job posting/layoffs
Check if Hyloris Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Hyloris Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hyloris Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hyloris Pharmaceuticals.
Hyloris Pharmaceuticals financials insights
Gather financial insights about Hyloris Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$16.4M
Hyloris Pharmaceuticals Tech Stack
A closer look at the technologies used by Hyloris Pharmaceuticals
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Pain Point
Project
, according to a high-level source in Operations Management, is planning to remediate challenges related to accounting and finance software.
Pain Point, Accounting, Financial Systems, Software, Financial Reporting, Finance, Operations
Project
, according to a high-level source in Operations Management, is planning to implement the process of a quarterly depreciation of existing assets.
Implementation, Operations
Pain Point
Project
, according to a high-level source in Operations Management, is planning to remediate challenges related to business process management (BPM).
Pain Point, Analytics & Insights, Workforce Management, Corporate Strategy, Operations
Project
Document Management, Software, Operations
Hyloris Pharmaceuticals News & Media
Regulated Information Hyloris Appoints Christophe Maréchal as Chief Financial Officer ...
Press Release - Regulated Information - Inside Information Hyloris Appoints Christophe Maréchal as Chief Financial Officer Liège,...Hyloris announces US FDA approval for Podofilox Gel
Hyloris announces US FDA approval for Podofilox GelHyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)
Liège, Belgium – 22 June 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo. AlenuraTM is a patented, innovative, clinical-stagHyloris shareholders approve all resolutions at the Annual General Meeting
Regulated Information – Inside Information - Liège, Belgium – 13 June 2023 – 6PM CET - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces the approval of all resolutions proposed at its Annual General Meeting (AGM) held at its headquarters in Liège, Belgium on 13 June 2023.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hyloris Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Hyloris is a specialty pharmaceutical company dedicated to innovating and optimizing existing medications to meet unmet healthcare needs. The company focuses on reformulation, repurposing, and developing new chemical entities, leveraging established regulatory pathways to streamline market entry. With a diverse portfolio of 28 products, including v... Read More
